TLK1 and non-small cell lung carcinoma: Particularly, a previous investigation identified tertiary amine-linked indirubin-3’-oximes as potent anticancer agents targeting TLK activity, which exhibited marked growth-inhibitory effects on NSCLC A549 cells through TLK1 pathway suppression [39].